Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

Inclusion Criteria: * Be 18 to 65 years of age; * Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study; * Demonstrate understanding of study procedures by correctly answering all questions on the consent competency tool; * Be interested in reducing or stopping methamphetamine use; * Meet DSM-5 criteria for severe methamphetamine use disorder; * Meet subjective and objective methamphetamine use criteria as defined by the protocol; * Meet subjective and objective measures of being opioid-free prior to enrollment and medication induction per study medical clinician's determination (including passing a naloxone challenge); * Agree to use study cellphone to record videos of take-home dosing for transfer to study team. * If female of childbearing potential, agree to use acceptable birth control methods during participation in the study; Exclusion Criteria: * Have known allergy or sensitivity to study medications; * Have a medical history or condition that would make study participation difficult or unsafe; * Have an acute psychiatric disorder or condition that would make study participation difficult or unsafe; * Liver function test results greater than 5 times the upper limit of normal or other exclusionary clinical lab test values; * Recent or ongoing treatment with medications that, in the judgment of the study medical clinician, could interact adversely with study drugs or interfere with study participation; * Have a current pattern of alcohol, benzodiazepine, or other sedative-hypnotic use, as determined by the study medical clinician, which would preclude safe participation; * Pending action or situation that might prevent remaining in the area for the duration of the study or prevent participation in study activities * Be currently pregnant or breastfeeding;